Methionine adenosyltransferase I/III (MAT I/III) deficiency is an inherited disorder of methionine metabolism caused by variants in the MAT1A gene. It produces persistent hypermethioninemia, usually isolated and benign in course, although some biallelic cases may be associated with decreased S-adenosylmethionine (SAM) and neurological manifestations.
Methionine adenosyltransferase 1-3 deficiency
The MAT1A gene encodes the hepatic methionine adenosyltransferase I and III isoenzymes, which catalyze the conversion of methionine into S-adenosylmethionine (SAM), the body's main methyl group donor. SAM participates in numerous methylation reactions, including neurotransmitter synthesis and processes related to central nervous system myelination.
Pathogenic variants in MAT1A reduce enzyme activity, leading to methionine accumulation in the blood, and in some patients, SAM levels may decrease. Unlike other causes of hypermethioninemia, it usually presents with normal or not significantly elevated homocysteine. The deficiency can be inherited in an autosomal dominant or autosomal recessive manner: dominant forms are usually mild or asymptomatic, while recessive forms due to biallelic variants carry a higher risk of neurological or hepatic manifestations. Many cases are detected through newborn screening.
Symptoms
The onset usually corresponds to the neonatal period due to detection in screening, although most individuals remain asymptomatic. When clinical manifestations appear, they may include developmental delay, language disorders, hypotonia, learning problems, movement disorders, or seizures. In some biallelic cases, cerebral demyelination has been described; liver involvement, such as steatosis or cirrhosis, is infrequent.
Disease management
There is no specific preventive strategy to avoid the genetic disease, but monitoring aims to prevent complications associated with very high methionine or SAM deficiency. In mild cases, periodic monitoring of methionine, homocysteine, and neurological evolution may suffice. If methionine is persistently very high or symptoms exist, moderate methionine restriction may be indicated and, in selected cases, supplementation with SAM under specialized supervision.
Genes analyzed
Bibliography
Furujo M, Kinoshita M, Nagao M, et al. Methionine adenosyltransferase I/III deficiency: neurological manifestations and relevance of S-adenosylmethionine. Mol Genet Metab. 2012 Nov;107(3):253-6.
Kim YM, Kim JH, Choi J, et al. Determination of Autosomal Dominant or Recessive Methionine Adenosyltransferase I/III Deficiencies Based on Clinical and Molecular Studies. Mol Med. 2016 Sep;22:147-155.
Muriello MJ, Viall S, Bottiglieri T, et al. Confirmation that MAT1A p.Ala259Val mutation causes autosomal dominant hypermethioninemia. Mol Genet Metab Rep. 2017 Jul 15;13:9-12.
